BioMarin Narrows Roctavian Efforts to U.S., Germany, Italy as Sales Stagnate

BioMarin Pharmaceuticals on Monday said it is restricting sales of its hemophilia A gene therapy to three countries in an effort to reduce costs and help the treatment become profitable by 2025.